Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Yanyun, Gao"'
Autor:
Darya Karatkevich, Tereza Losmanova, Philipp Zens, Haibin Deng, Christelle Dubey, Tuo Zhang, Corsin Casty, Yanyun Gao, Christina Neppl, Sabina Berezowska, Wenxiang Wang, Ren-Wang Peng, Ralph Alexander Schmid, Patrick Dorn, Thomas Michael Marti
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract The combination of cisplatin and pemetrexed remains the gold standard chemotherapy for malignant pleural mesothelioma (MPM), although resistance and poor response pose a significant challenge. Cytidine deaminase (CDA) is a key enzyme in the
Externí odkaz:
https://doaj.org/article/b97b92bc2b4847fca5438e0799a61a42
Autor:
Duo Xu, MD, PhD, Yanyun Gao, PhD, Haitang Yang, MD, PhD, Marc Spils, MD, Thomas M. Marti, PhD, Tereza Losmanová, MD, Min Su, PhD, Wenxiang Wang, MD, Qinghua Zhou, MD, Patrick Dorn, MD, Yongqian Shu, MD, PhD, Ren-Wang Peng, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 5, Pp 100672- (2024)
Introduction: Malignant pleural mesothelioma (MPM) is a rare and universally lethal malignancy with limited treatment options. Immunotherapy with immune checkpoint inhibitors (ICIs) has recently been approved for unresectable MPM, but response to ICI
Externí odkaz:
https://doaj.org/article/e39747f2ea884a66863f10c057030d43
Autor:
Haitang Yang, Yanyun Gao, Duo Xu, Ke Xu, Shun-Qing Liang, Zhang Yang, Amina Scherz, Sean R. R. Hall, Stefan Forster, Sabina Berezowska, Feng Yao, Adrian F. Ochsenbein, Thomas M. Marti, Gregor J. Kocher, Ralph A. Schmid, Patrick Dorn, Ren-Wang Peng
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-15 (2023)
Abstract Malignant pleural mesothelioma (MPM) is a lethal malignancy etiologically caused by asbestos exposure, for which there are few effective treatment options. Although asbestos carcinogenesis is associated with reactive oxygen species (ROS), th
Externí odkaz:
https://doaj.org/article/5254c7ce468140869bc77e5e71f90aa3
Autor:
Zhang Yang, Shun-Qing Liang, Liang Zhao, Haitang Yang, Thomas M. Marti, Balazs Hegedüs, Yanyun Gao, Bin Zheng, Chun Chen, Wenxiang Wang, Patrick Dorn, Gregor J. Kocher, Ralph A. Schmid, Ren-Wang Peng
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-18 (2022)
Abstract Background Oncogenic KRAS mutations are prevalent in human cancers, but effective treatment of KRAS-mutant malignancies remains a major challenge in the clinic. Increasing evidence suggests that aberrant metabolism plays a central role in KR
Externí odkaz:
https://doaj.org/article/bc76e919384f491d926df24e6badec93
Autor:
Yanyun Gao, Philipp Zens, Min Su, Camila Anna Gemperli, Haitang Yang, Haibin Deng, Zhang Yang, Duo Xu, Sean R. R. Hall, Sabina Berezowska, Patrick Dorn, Ren-Wang Peng, Ralph Alexander Schmid, Wenxiang Wang, Thomas Michael Marti
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-22 (2021)
Abstract Background Pemetrexed (MTA) plus cisplatin combination therapy is considered the standard of care for patients with advanced non-small-cell lung cancer (NSCLC). However, in advanced NSCLC, the 5-year survival rate is below 10%, mainly due to
Externí odkaz:
https://doaj.org/article/77898471515947d0a1e1ce7aa86c96c0
Autor:
Haoran Li, Xueling Wang, Xiaodan Huang, Yanli He, Yiran Zhang, Cui Hao, Pengjiao Zeng, Meng Zhang, Yanyun Gao, Dandan Yang, Ming Shan, Huaiqian Dou, Xiaoyu Li, Xiaotian Chang, Zibin Tian, Lijuan Zhang
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionEarly diagnosis could lead to a cure of colorectal cancer (CRC). Since CRC is related to aging and lifestyles, we tested if the environmental information-enriched monosaccharide composite (MC) of circulating glycans could serve as an earl
Externí odkaz:
https://doaj.org/article/13ee61fa4cfd42c8bde1c596d0089fb6
Autor:
Yanyun Gao, Patrick Dorn, Shengchen Liu, Haibin Deng, Sean R. R. Hall, Ren-Wang Peng, Ralph A. Schmid, Thomas M. Marti
Publikováno v:
Cancer Cell International, Vol 19, Iss 1, Pp 1-14 (2019)
Abstract Background Cisplatin plus pemetrexed combination therapy is considered the standard treatment for patients with advanced, non-squamous, non-small-cell lung cancer (NSCLC). However, advanced NSCLC has a 5-year survival rate of below 10%, whic
Externí odkaz:
https://doaj.org/article/771e52eeb8d044dcbefe6075fc730568
Autor:
Zhang Yang, Shun‐Qing Liang, Maria Saliakoura, Haitang Yang, Eric Vassella, Georgia Konstantinidou, Mario Tschan, Balazs Hegedüs, Liang Zhao, Yanyun Gao, Duo Xu, Haibin Deng, Thomas M Marti, Gregor J Kocher, Wenxiang Wang, Ralph A Schmid, Ren‐Wang Peng
Publikováno v:
EMBO Molecular Medicine, Vol 13, Iss 9, Pp n/a-n/a (2021)
Abstract KRAS oncoprotein is commonly mutated in human cancer, but effective therapies specifically targeting KRAS‐driven tumors remain elusive. Here, we show that combined treatment with fibroblast growth factor receptor 1 (FGFR1) and polo‐like
Externí odkaz:
https://doaj.org/article/23b8f303848f40aa8b6c0bc1e5ce0a87
Autor:
Darya Karatkevich, Haibin Deng, Yanyun Gao, Emilio Flint, Ren-Wang Peng, Ralph Alexander Schmid, Patrick Dorn, Thomas Michael Marti
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 19, p 11949 (2022)
Malignant pleural mesothelioma (MPM) is a rare but aggressive thoracic malignancy with limited treatment options. One of the standard treatments for MPM is chemotherapy, which consists of concurrent treatment with pemetrexed and cisplatin. Pemetrexed
Externí odkaz:
https://doaj.org/article/4de28614084247eda1ff5601460eff9e
Publikováno v:
Cancers, Vol 14, Iss 15, p 3758 (2022)
MPM is an aggressive tumor originating from pleural mesothelial cells. A characteristic feature of the disease is the dominant prevalence of therapeutically intractable inactivating alterations in TSGs, making MPM one of the most difficult cancers to
Externí odkaz:
https://doaj.org/article/59eb3758f9764c9da0739d5e9d92df23